First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study

Shukui Qin(Memorial Sloan Kettering Cancer Center), Shouguo Li(Yunnan Agricultural University), Hongming Pan(Sir Run Run Shaw Hospital), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Lin Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Xinjun Liang(Hubei Cancer Hospital), Xiaoyan Lin(Fujian Medical University), Yanli Qu(Liaoning Cancer Hospital & Institute), Jin Li(Shanghai Cancer Institute), Yuxian Bai(Harbin Medical University), Wěi Li(Zhengzhou University), Xi Chen(117th Hospital of People's Liberation Army), Feng Ye(First Affiliated Hospital of Xiamen University), Suxia Luo(Zhengzhou University), Tianshu Liu(Sun Yat-sen University), Lin Zhao(Nanjing University of Chinese Medicine), Jianwei Yang(Beijing Institute of Technology), Yixiang Mao, Sonal Bordia(Merck & Co., Inc., Rahway, NJ, USA (United States)), Run Guo, Yi Zuo
Advances in Therapy
March 1, 2025
10.1007/s12325-024-03069-4
Cited by 9

Related Papers

Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
|Molecular Cancer|2019|1.2k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1.1k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
|Nature|2021|687